[China Pharmaceutical Network Technology News] In recent years, China's pharmaceutical industry has entered a period of rapid development, and China has become the world's second largest pharmaceutical market after the United States. However, in terms of environmental pollution, the pharmaceutical industry, a large “sewage emitterâ€, has been pushed to the forefront of the turmoil. Environmental protection has become a serious challenge for pharmaceutical companies.
According to data released by the Ministry of Environmental Protection, the total output value of China's pharmaceutical industry accounts for less than 3% of the national GDP, while the total amount of pollution emissions accounts for about 6%. Among them, the problem of high-pollution and high-energy APIs is particularly prominent. .
Wu Yafeng, Director and President of Tianhua Holdings Group
Two major pollution problems have trapped large GDP
Since the reform and opening up, China's pharmaceutical industry has entered a period of rapid development. China has become the world's second largest pharmaceutical market after the United States and one of the fastest growing regions in the world. With the rapid development of the pharmaceutical industry and the contribution to GDP, environmental protection has become a major problem for many pharmaceutical companies. There are many environmental problems in the pharmaceutical industry. Wu Yafeng, the director and president of the Tianji Group, explained the current difficulties in the environmental protection of the pharmaceutical industry. There are two main difficulties: one is the control of odor, and the key work is mainly the treatment of stench and VOCs. At present, the governance technology is mixed; the other is the disposal of pharmaceutical wastewater and waste residue. At present, there is no mature and effective method to achieve near-zero emissions. The two-pronged approach of source control and end-of-pipe treatment is the future work direction of the pharmaceutical environmental protection field. The source-controlled emission reduction technology and recycling technology will gradually emerge. The zero-emission technology, comprehensive utilization or recycling technology of terminal treatment will gradually occupy the pharmaceutical environmental protection market.
In May 2015, Hebei Province launched a comprehensive management plan for key industries VOCs, clarifying that petrochemical, pharmaceutical, organic chemical and other industries have become key remediation industries. According to the Hebei Province's governance plan, by 2016, Hebei Province will complete the renovation and construction of VOCs treatment facilities for 72 pharmaceutical and chemical companies. The VOCs emissions of the pharmaceutical industry account for not much of the total emissions of VOCs, about 10%, and the proportion of VOCs in key pharmaceutical production cities such as Shijiazhuang will reach about 15%. The pharmaceutical industry has different characteristics from the VOCs emitted by other industries. Wu Yafeng mentioned that compared with petrochemicals and packaging printing, there are many kinds of VOCs in the pharmaceutical industry, and the concentration changes greatly, and some substances are temporarily unable to define their chemical composition. In addition, in addition to VOCs, the pharmaceutical industry's exhaust gas may also contain other pollutants, such as dust, organic acids and alkalis, and some high exhaust gas temperature and humidity, these factors have made the VOCs in the pharmaceutical industry difficult to control.
MSQ series technology disruptively solves environmental problems in medicine
Morans Environmental Protection is an environmental protection company under the Tianshishi Holding Group. It always adheres to the T-EPC system of the Tianji Holdings Group, which provides docking services for the pharmaceutical industry from technology development, engineering design, environmental protection, automation and engineering. The Group's grouped and vertically managed management system is unique in China. The corporate culture that the company has always adhered to in a win-win and open-door manner has also become the core competitiveness of the company.
For the characteristics of VOCs in the pharmaceutical industry, the MSQ series VOCs exhaust gas treatment technology launched by Morans Environmental has been successfully applied in the pharmaceutical industry for the first time on October 6, 2015, which has solved the atmospheric and low concentrations in a subversive manner. Environmental pollution problems caused by VOCs. The so-called "subversive" is mainly reflected in the fact that the concentration of VOCs can be reduced to very low after treatment, and can reach below 1mg/m3, which is close to zero emission. Currently, other technologies cannot do this in the treatment of fermentation tail gas. Wu Yafeng mentioned: This series of technologies has been applied for more than ten years in foreign countries, including clothing and petrochemical industries. It is the first time in large-scale application in the pharmaceutical industry. One of the MSQ series VOCs exhaust gas treatment technologies introduced by Morans Environmental is for the concentrated air volume and low concentration MSQ-1 series, and the other is for small gas, medium and low concentration MSQ-2 series, two series. There are currently success stories.
The treatment of pharmaceutical wastewater is another difficult point in pharmaceutical environmental protection. The wastewater in the pharmaceutical industry mainly has the characteristics of being difficult to biochemical, high salinity and high ammonia nitrogen. If not treated properly, it will cause secondary pollution. In response to this problem, Wu Yafeng said: The secondary pollution of wastewater treatment is mainly the odor pollution of wastewater treatment plants and the pollution of sewage treatment sludge. For the odor pollution, the wastewater treatment plant of Morans Environmental Protection Construction is fully enclosed and the malodorous gases are collected. Dispose of, do not discharge directly. The treatment of sludge is carried out by intensified thermal hydrolysis and then converted into biogas utilization or incineration disposal mode to reasonably control secondary pollution of sludge.
At present, the environmental protection work in the pharmaceutical industry is imminent, and the situation of the pharmaceutical environmental protection market is very good. Wu Yafeng believes that within 2-3 years of environmental protection in the pharmaceutical industry, there will be a large incremental market in China. Compared with the international market, China's pharmaceutical industry has been lagging behind foreign countries for more than ten years. The pollution problem of foreign pharmaceutical industry has been gradually solved. We have reason to believe that the environmental problems of the pharmaceutical industry in China will be solved and will be better solved. Morans Environmental is confident to help domestic pharmaceutical companies get rid of pollution and contribute to solving problems such as smog weather.
According to data released by the Ministry of Environmental Protection, the total output value of China's pharmaceutical industry accounts for less than 3% of the national GDP, while the total amount of pollution emissions accounts for about 6%. Among them, the problem of high-pollution and high-energy APIs is particularly prominent. .
Wu Yafeng, Director and President of Tianhua Holdings Group
Two major pollution problems have trapped large GDP
Since the reform and opening up, China's pharmaceutical industry has entered a period of rapid development. China has become the world's second largest pharmaceutical market after the United States and one of the fastest growing regions in the world. With the rapid development of the pharmaceutical industry and the contribution to GDP, environmental protection has become a major problem for many pharmaceutical companies. There are many environmental problems in the pharmaceutical industry. Wu Yafeng, the director and president of the Tianji Group, explained the current difficulties in the environmental protection of the pharmaceutical industry. There are two main difficulties: one is the control of odor, and the key work is mainly the treatment of stench and VOCs. At present, the governance technology is mixed; the other is the disposal of pharmaceutical wastewater and waste residue. At present, there is no mature and effective method to achieve near-zero emissions. The two-pronged approach of source control and end-of-pipe treatment is the future work direction of the pharmaceutical environmental protection field. The source-controlled emission reduction technology and recycling technology will gradually emerge. The zero-emission technology, comprehensive utilization or recycling technology of terminal treatment will gradually occupy the pharmaceutical environmental protection market.
In May 2015, Hebei Province launched a comprehensive management plan for key industries VOCs, clarifying that petrochemical, pharmaceutical, organic chemical and other industries have become key remediation industries. According to the Hebei Province's governance plan, by 2016, Hebei Province will complete the renovation and construction of VOCs treatment facilities for 72 pharmaceutical and chemical companies. The VOCs emissions of the pharmaceutical industry account for not much of the total emissions of VOCs, about 10%, and the proportion of VOCs in key pharmaceutical production cities such as Shijiazhuang will reach about 15%. The pharmaceutical industry has different characteristics from the VOCs emitted by other industries. Wu Yafeng mentioned that compared with petrochemicals and packaging printing, there are many kinds of VOCs in the pharmaceutical industry, and the concentration changes greatly, and some substances are temporarily unable to define their chemical composition. In addition, in addition to VOCs, the pharmaceutical industry's exhaust gas may also contain other pollutants, such as dust, organic acids and alkalis, and some high exhaust gas temperature and humidity, these factors have made the VOCs in the pharmaceutical industry difficult to control.
MSQ series technology disruptively solves environmental problems in medicine
Morans Environmental Protection is an environmental protection company under the Tianshishi Holding Group. It always adheres to the T-EPC system of the Tianji Holdings Group, which provides docking services for the pharmaceutical industry from technology development, engineering design, environmental protection, automation and engineering. The Group's grouped and vertically managed management system is unique in China. The corporate culture that the company has always adhered to in a win-win and open-door manner has also become the core competitiveness of the company.
For the characteristics of VOCs in the pharmaceutical industry, the MSQ series VOCs exhaust gas treatment technology launched by Morans Environmental has been successfully applied in the pharmaceutical industry for the first time on October 6, 2015, which has solved the atmospheric and low concentrations in a subversive manner. Environmental pollution problems caused by VOCs. The so-called "subversive" is mainly reflected in the fact that the concentration of VOCs can be reduced to very low after treatment, and can reach below 1mg/m3, which is close to zero emission. Currently, other technologies cannot do this in the treatment of fermentation tail gas. Wu Yafeng mentioned: This series of technologies has been applied for more than ten years in foreign countries, including clothing and petrochemical industries. It is the first time in large-scale application in the pharmaceutical industry. One of the MSQ series VOCs exhaust gas treatment technologies introduced by Morans Environmental is for the concentrated air volume and low concentration MSQ-1 series, and the other is for small gas, medium and low concentration MSQ-2 series, two series. There are currently success stories.
The treatment of pharmaceutical wastewater is another difficult point in pharmaceutical environmental protection. The wastewater in the pharmaceutical industry mainly has the characteristics of being difficult to biochemical, high salinity and high ammonia nitrogen. If not treated properly, it will cause secondary pollution. In response to this problem, Wu Yafeng said: The secondary pollution of wastewater treatment is mainly the odor pollution of wastewater treatment plants and the pollution of sewage treatment sludge. For the odor pollution, the wastewater treatment plant of Morans Environmental Protection Construction is fully enclosed and the malodorous gases are collected. Dispose of, do not discharge directly. The treatment of sludge is carried out by intensified thermal hydrolysis and then converted into biogas utilization or incineration disposal mode to reasonably control secondary pollution of sludge.
At present, the environmental protection work in the pharmaceutical industry is imminent, and the situation of the pharmaceutical environmental protection market is very good. Wu Yafeng believes that within 2-3 years of environmental protection in the pharmaceutical industry, there will be a large incremental market in China. Compared with the international market, China's pharmaceutical industry has been lagging behind foreign countries for more than ten years. The pollution problem of foreign pharmaceutical industry has been gradually solved. We have reason to believe that the environmental problems of the pharmaceutical industry in China will be solved and will be better solved. Morans Environmental is confident to help domestic pharmaceutical companies get rid of pollution and contribute to solving problems such as smog weather.
Ivd Consumables,Virus Collection System,Virus Preservation System,Virus Collection And Preservation System
HANGZHOU DIAN BIOTECHNOLOGY CO., LTD. , https://www.dianbiotech.com